Invention Grant
US09562237B2 Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
有权
减少骨髓细胞TGFβ信号在治疗癌症中的作用
- Patent Title: Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
- Patent Title (中): 减少骨髓细胞TGFβ信号在治疗癌症中的作用
-
Application No.: US14820697Application Date: 2015-08-07
-
Publication No.: US09562237B2Publication Date: 2017-02-07
- Inventor: Li Yang
- Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Leydig, Voit & Mayer, Ltd.
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/85 ; C12Q1/68 ; G01N33/50 ; G01N33/574 ; A61K31/5377 ; A61K31/7088 ; C12N15/113 ; C07K14/71 ; A61K35/15 ; A61K35/28 ; A01K67/027
Abstract:
Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.
Public/Granted literature
- US20150344891A1 REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER Public/Granted day:2015-12-03
Information query
